Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin.
We report a leukemic patient with C. krusei fungemia who failed to respond to liposomal amphotericin B therapy alone. The addition of caspofungin eradicated infection and was well tolerated. Our report is the first to describe successful treatment of a patient with invasive C. krusei infection using this combination of antifungals. Combination therapy could be a useful treatment option for invasive candidosis, particularly when caused by more resistant species such as C. krusei.
Olver
W J
WJ
Department of Medical Microbiology, Ninewells Hospital, Dundee, UK. william.j.olver@tuht.scot.nhs.uk
Scott
F
F
Shankland
G S
GS
D000328:Adult; D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D000077336:Caspofungin; D004359:Drug Therapy, Combination; D054714:Echinocandins; D016469:Fungemia / Q000188:drug therapy*; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000188:drug therapy; D055666:Lipopeptides; D008297:Male; D010456:Peptides, Cyclic / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D000666:Amphotericin B; D000077336:Caspofungin